Elevated classical soluble HLA class I molecules in breast cancer patients are associated with favorable disease outcome
Year: 2026
Type: article
Study design: Observational Study
Abstract: BACKGROUND: T cell recognition of human leukocyte antigen (HLA)-presented peptides plays a central role in immunosurveillance of malignant disease. Besides HLA molecules on cell surfaces, soluble HLA molecules (sHLA) are released in the blood and suggested to impact cellular immune responses. METHODS: Here, we investigate classical sHLA class I (HLA-A, -B, -C) molecules in pretreatment serum from 191 patients, either with invasive breast cancer (BC, n = 140) or with ductal carcinoma in situ (DCIS, n = 51), in relation to clinical parameters and survival with a follow-up time of up to 10 years. RESULTS: Classical sHLA class I serum levels were significantly elevated in patients with DCIS and invasive BC compared to a healthy control cohort. sHLA levels did not differ across molecular subtypes or menopausal status. Of note, higher sHLA class I levels at time of diagnosis were associated with prolonged overall survival independent of age and metastatic status. CONCLUSIONS: The findings of this study reveal first insights on classical sHLA class I molecules in BC patients suggesting an association of higher sHLA class I levels with favorable overall survival that warrants mechanistic investigation and identify sHLA as a potential candidate biomarker for further validation.
Source: BMC Cancer
Language: English
Subfield: Cancer Research
Domain: Life Sciences
Open Access status: gold
Estimated APC paid: $3,390
Funder: Universitätsklinikum Tübingen
OpenAlex ID: W7237169550
